- Home
- NVNI vs INKT Comparison
NVNI vs INKT Comparison
Compare NVNI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNI
- INKT
- Stock Information
- Founded
- NVNI 2019
- INKT 2017
- Country
- NVNI Brazil
- INKT United States
- Employees
- NVNI N/A
- INKT N/A
- Industry
- NVNI
- INKT Medicinal Chemicals and Botanical Products
- Sector
- NVNI
- INKT Health Care
- Exchange
- NVNI Nasdaq
- INKT Nasdaq
- Market Cap
- NVNI 57.2M
- INKT 51.7M
- IPO Year
- NVNI N/A
- INKT 2021
- Fundamental
- Price
- NVNI $2.92
- INKT $10.78
- Analyst Decision
- NVNI
- INKT Buy
- Analyst Count
- NVNI 0
- INKT 2
- Target Price
- NVNI N/A
- INKT $35.00
- AVG Volume (30 Days)
- NVNI 107.3K
- INKT 21.0K
- Earning Date
- NVNI 09-30-2025
- INKT 11-14-2025
- Dividend Yield
- NVNI N/A
- INKT N/A
- EPS Growth
- NVNI N/A
- INKT N/A
- EPS
- NVNI N/A
- INKT N/A
- Revenue
- NVNI $31,250,627.00
- INKT N/A
- Revenue This Year
- NVNI $12.05
- INKT N/A
- Revenue Next Year
- NVNI $15.02
- INKT N/A
- P/E Ratio
- NVNI N/A
- INKT N/A
- Revenue Growth
- NVNI 1491.58
- INKT N/A
- 52 Week Low
- NVNI $1.44
- INKT $4.56
- 52 Week High
- NVNI $121.90
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- NVNI 45.29
- INKT 31.05
- Support Level
- NVNI $2.80
- INKT $10.54
- Resistance Level
- NVNI $3.07
- INKT $11.52
- Average True Range (ATR)
- NVNI 0.25
- INKT 0.84
- MACD
- NVNI -0.07
- INKT -0.14
- Stochastic Oscillator
- NVNI 24.64
- INKT 2.71
About NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.